Is Novavax's Biggest Catalyst Ever Just Ahead?
Novavax (NASDAQ: NVAX) has reported a string of good news since late last year. More than 35 countries have authorized its coronavirus vaccine
Novavax has shipped doses, and healthcare facilities around the world are administering them. The vaccine is showing efficacy against omicron and other variants. And the company predicts 2022 revenue in the range of $4 billion to $5 billion.
Yet the shares haven't joined in on the celebrations. Novavax stock has dropped more than 40% since the start of the year. At the same time, a catalyst may be only days away.
Source Fool.com
